Search results
Results from the WOW.Com Content Network
Richard J. Ablin (May 15, 1940 – October 6, 2023) [1] was an American scientist, most notable for research on prostate cancer.According to the Wall Street Journal: . Richard Ablin, a professor of pathology at University of Arizona College of Medicine, discovered the prostate-specific antigen (PSA) in 1970, and for nearly as long, he has argued that it should not be used for routine screening.
In men aged 55–69 who have been counseled on the known harms and potential benefits of prostate cancer screening, the U.S. Preventive Service Task Force May 2018 statement states, "The use of digital rectal examination as a screening modality is not recommended because there is a lack of evidence on the benefits."
As the name indicates, it is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection. It has been the standard treatment for BPH for many years, but recently alternative, minimally invasive techniques have become available. [1] This procedure is done with spinal or general anaesthetic.
The test measures the amount of PSA, a protein that your prostate makes, in your blood, explains Richard Levin, M.D., a urologist and vice chief of staff of the medical executive committee at HCA ...
There are several reasons why PIN is the most likely prostate cancer precursor. [3] PIN is more common in men with prostate cancer. High grade PIN can be found in 85 to 100% of radical prostatectomy specimens, [4] nearby or even in connection with prostate cancer. It tends to occur in the peripheral zone of the prostate.
The prostate is a gland that is deep within the pelvic cavity of those with male anatomy. It is responsible for producing fluid that helps with sperm movement. Due to its location within the body, when diseased, it can affect the reproductive and urinary systems. [3]
For premium support please call: 800-290-4726 more ways to reach us
Prostate cancer antigen 3 is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate cancer. [32] [46] [47] [44] ConfirmMDx is performed on tissue taken during a prostate biopsy. The test identifies men with clinically significant prostate cancer who would benefit from further testing and treatment.